Inventiva

US · IVA #3421 by market cap Listed 2020

3.37 -0.10 -2.75%

Live - 5344 symbols - heartbeat 132s ago · 2026-10-08 08:59

Pre-market 3.30 -1.93%

After-hours 3.37 0.00%

Overnight 3.39 +0.74%

Market cap: 794.93M
P/E (TTM): -5.63
P/B: 12.02
EPS: -2.13
Div yield: 0.00%
52W pos: 5%

Reader sentiment Are you bullish or bearish on IVA?

Anonymous reader poll. Unscientific, not investment advice.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.

Founded: 2011
CEO: Mr. Andrew Obenshain
Employees: 77
Headquarters: Daix, BF, France
Fiscal year end: 12-31
Website: inventivapharma.com

Company profile

Exchange: US
Symbol: IVA
Market-cap rank: #3421
Listing date: 2020-07-10
Market cap: 794.93M
Float cap: 557.00M
Shares out: 236.23M
Float shares: 165.53M

Sectors & themes

Biotechnology Stocks tradable only on moomoo

Browse all sectors & themes

Quote time 2026-10-08 08:59:17 · For reference only, not investment advice and not tailored to your situation.